Immunocore (ADR)
Develops ImmTAX-based immunotherapies and sells KIMMTRAK for eligible uveal melanoma patients.
$36.62
After-hours close−0.01 (−0.03%)
At close$36.63(−0.33%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 102.51%Insiders 0.37%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 50.83M · Float 50.34M · 99.0% free float
Institutions13F, as of Jun 30, 2026
145 holders · 52.11M shares · 26 new positions · 78 increased · 40 reduced · 34 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Wellington Management Group LLP | 5.72M | 11.26% | +1.02M | Aug 14, 2026 |
| RTW Investments, LP | 4.87M | 9.58% | 0 | Aug 14, 2026 |
| FMR LLC | 4.31M | 8.47% | −521.9K | Aug 13, 2026 |
| Primecap Management Co/CA/ | 3.64M | 7.16% | −55.0K | Aug 14, 2026 |
| Bellevue Group AG | 2.79M | 5.49% | −8.6K | Aug 14, 2026 |
| Tang Capital Management LLC | 2.65M | 5.21% | 0 | Aug 14, 2026 |
| Vestal Point Capital, LP | 1.80M | 3.54% | −966.9K | Aug 14, 2026 |
| Two Sigma Investments, LP | 1.65M | 3.24% | +627.7K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Wellington Management Group LLP | 10.20% | 5.13M | 13G | Aug 5, 2025 ↗ |
| Jallal Bahija | 8.20% | 4.49M | 13G | Feb 14, 2025 ↗ |
| Primecap Management Co/CA/ | 7.51% | 3.77M | 13G | Aug 14, 2025 ↗ |
| Bellevue Group AG | 5.60% | 2.80M | 13G | Nov 14, 2025 ↗ |
| Vestal Point Capital, LP | 5.50% | 2.77M | 13G | May 15, 2026 ↗ |
| Tang Capital Management, LLC | 5.20% | 2.61M | 13G | Oct 24, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | director | 170.0K | 0.33% | Mar 19, 2025 |
| Bahija Jallal | director, officer: CHIEF EXECUTIVE OFFICER | 12.3K | 0.02% | Feb 19, 2026 |
| David M. Berman | officer: HEAD OF R&D | 5.9K | 0.01% | Feb 19, 2026 |
| Tina Amber st Leger | officer: CHIEF HR OFFICER | 1.1K | 0.00% | Feb 19, 2026 |
| John Goll | officer: SVP, FINANCE & CAO | 653 | 0.00% | Feb 19, 2026 |
3 people have not refiled in the last 18 months (33.0K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Feb 18, 2026 | David M. Bermanofficer: HEAD OF R&D | Sale | 5,965 | $32.35 | 5,859 |
| Feb 18, 2026 | Tina Amber st Legerofficer: CHIEF HR OFFICER | Sale | 1,000 | $32.35 | 1,119 |
| Feb 18, 2026 | John Gollofficer: SVP, FINANCE & CAO | Sale | 698 | $32.35 | 653 |
| Feb 18, 2026 | Bahija Jallaldirector, officer: CHIEF EXECUTIVE OFFICER | Sale | 11,474 | $32.35 | 12,343 |
| Dec 4, 2025 | David M. Bermanofficer: HEAD OF R&D | Sale | 31,341 | $40.26 | 0 |
| Dec 5, 2025 | David M. Bermanofficer: HEAD OF R&D | Sale | 572 | $40.14 | 0 |
| Nov 26, 2025 | David M. Bermanofficer: HEAD OF R&D | Sale | 69,404 | $40.12 | 0 |
| Nov 28, 2025 | David M. Bermanofficer: HEAD OF R&D | Sale | 5,521 | $40.09 | 0 |
| Nov 25, 2025 | David M. Bermanofficer: HEAD OF R&D | Sale | 18,020 | $40.03 | 0 |
| Nov 24, 2025 | David M. Bermanofficer: HEAD OF R&D | Sale | 100 | $40.00 | 0 |
CongressHouse and Senate disclosures
Not reported.